Tempus AI, Inc. $TEM Stock Holdings Lifted by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lifted its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 79.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 21,032 shares of the company’s stock after buying an additional 9,320 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Tempus AI were worth $1,242,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of TEM. Royal Bank of Canada lifted its position in shares of Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after buying an additional 17,359 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Tempus AI in the 1st quarter worth about $116,000. Prudential Financial Inc. bought a new position in shares of Tempus AI in the 2nd quarter worth about $276,000. Russell Investments Group Ltd. lifted its position in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after buying an additional 1,146 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Tempus AI by 2,926.6% in the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after buying an additional 204,629 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. HC Wainwright raised their price target on shares of Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Robert W. Baird assumed coverage on shares of Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target on the stock. Morgan Stanley reduced their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research report on Wednesday, February 25th. Finally, TD Cowen upgraded shares of Tempus AI from a “hold” rating to a “buy” rating and set a $65.00 price objective on the stock in a research report on Monday, April 13th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.36.

Tempus AI Trading Down 0.8%

Shares of NASDAQ:TEM opened at $55.02 on Friday. The company has a market cap of $9.84 billion, a PE ratio of -39.02 and a beta of 4.00. The company’s 50-day moving average price is $50.65 and its 200 day moving average price is $63.58. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi?year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision?medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor?day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre?arranged Rule 10b5?1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair?value slightly and note the recent rally may be a short?term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total transaction of $8,500,362.50. Following the transaction, the chief executive officer owned 8,841,783 shares of the company’s stock, valued at approximately $452,080,364.79. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 10,084 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer directly owned 101,166 shares in the company, valued at approximately $5,973,852.30. The trade was a 9.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 563,841 shares of company stock worth $29,859,324 over the last 90 days. Corporate insiders own 24.26% of the company’s stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.